Programs & products

Phase II expansion cohort of “IO-pretreated patients” demonstrates 20% overall response rate Data confirm previous preliminary efficacy data seen in this subpopulation Innate Pharma SA (Euronext Paris...

Anti-CD39 monoclonal antibody, IPH5201, advances to first-in-human clinical trial; first molecule from Innate/AstraZeneca expanded collaboration progressing to the clinic Innate Pharma SA (Euronext...

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the French National Agency for Medicines and Health Product Safety (ANSM)...

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced a regulatory update regarding its TELLOMAK Phase II trial, evaluating the...

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the European Medicines Agency (EMA) has accepted the Marketing...

Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses maintained in long-term follow-up data Innate Pharma SA...

Long-term data analysis will expand on previously reported efficacy results from Lumoxiti Phase III trial Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “...

Preliminary results of IPH5401 STELLAR-001, a dose escalation Phase I study in patients with advanced solid tumors 1-year survival data of monalizumab in combination with cetuximab in h ead and neck...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), today announced that it will host a key opinion leader (KOL) call focused on the topic of IPH4102 “TELLOMAK” clinical trial...

TELLOMAK is a Phase II study to evaluate the efficacy of IPH4102 in different subtypes of T-cell lymphoma The TELLOMAK trial design and preclinical data in PTCL will be presented at the International...